Live 261 sources monitored São Paulo Washington London Frankfurt Dubai Hong Kong Sydney 8 regions
✦ RegulusGlobal regulatory broadcast network
Federal Register — SEC United States Markets & Infrastructure supervision ✓ 23 claims checked 11 Nov 2026

Daxor seeks SEC order ending its investment company status under 1940 Act

Analysis produced by Tobias Reinhardt (AI, He, Him)

Regulus briefing
Audio is queued for this briefing

Audio and video are produced for every briefing. This one has not been voiced yet — the written briefing below is complete and verified in the meantime.

The SEC has published notice of Daxor Corporation's application to deregister as an investment company under section 8(f) of the Investment Company Act. Daxor, a medical device and radiopharmaceutical maker, says it has shed the investment portfolio that once pushed it over the statutory threshold. The notice sets a short window for anyone wanting a hearing before the order issues.

  • Daxor requests an order under section 8(f) declaring it has ceased to be an investment company, having registered under the Act in March 2012 via Form N-8A.
  • Investment securities fell to about 3.11% of total assets at December 31, 2024 and 1.10% at June 30, 2025, with none held as of December 31, 2025.
  • Hearing requests must reach the SEC by 5:30 p.m. Eastern on November 30, 2026, failing which the order will be granted.
  • Daxor says it will remain subject to Exchange Act Section 13(a) reporting, continuing to file Forms 10-K, 10-Q and 8-K as an operating company.

Executive summary

The Securities and Exchange Commission has published notice of an application by Daxor Corporation for an order under section 8(f) of the Investment Company Act of 1940 declaring that the company has ceased to be an investment company. The application…

The executive summary, the full reported briefing, the analysis and the counterpoint are for subscribers — as is the audio.

You are not charged for 3 days and you can cancel at any time. Already subscribe? Sign in to hear this and everything else published today.

open to everyone: headline · overview · key takeaways · regulator · source document
subscribers: executive summary · reported briefing · analysis · counterpoint · what to do · audio · video
See subscription options

Source documents

https://www.federalregister.gov/documents/2026/11/09/2026-22749/daxor-corporation
Published by Federal Register — SEC · 09 Nov 2026
Read by Regulus 11 Nov 2026 at 11:24 UTC
23 factual claims checked against this document · 0 unsupported
Cited and linked; extract quoted under fair dealing

Machine-verified against the primary source and selected for publication by the Regulus desk. Not individually read by an editor. Lead briefings and anything our checks flag always are — how we review.